Human papillomavirus (HPV) vaccination can prevent HPV infections and HPV-associated diseases.[53]Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015 Feb 19;372(8):711-23.
http://www.nejm.org/doi/full/10.1056/NEJMoa1405044#t=article
http://www.ncbi.nlm.nih.gov/pubmed/25693011?tool=bestpractice.com
[54]Centers for Disease Control and Prevention. Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV vaccine. Nov 2016 [internet publication].
http://www.cdc.gov/hpv/downloads/9vHPV-guidance.pdf
[55]Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009 Jun 6;373(9679):1949-57.
http://www.ncbi.nlm.nih.gov/pubmed/19493565?tool=bestpractice.com
[56]Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002 Nov 21;347(21):1645-51.
http://www.ncbi.nlm.nih.gov/pubmed/12444178?tool=bestpractice.com
[57]Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004 Nov 13-19;364(9447):1757-65.
http://www.ncbi.nlm.nih.gov/pubmed/15541448?tool=bestpractice.com
[58]Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018 May 9;(5):CD009069.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009069.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/29740819?tool=bestpractice.com
[59]Brisson M, Kim JJ, Canfell K, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020 Feb 22;395(10224):575-90.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30068-4/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/32007141?tool=bestpractice.com
[60]Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl 4):iv72-83.
https://www.annalsofoncology.org/article/S0923-7534(19)42148-0/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/28881916?tool=bestpractice.com
[
]
What are the advantages and disadvantages of the prophylactic human papillomavirus (HPV) vaccination in 15‐ to 26‐year‐old women?/cca.html?targetUrl=https://www.cochranelibrary.com/cca/doi/10.1002/cca.4171/fullShow me the answer Studies in countries with established HPV vaccination programmes report a substantially reduced incidence of cervical cancer.[16]Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020 Oct 1;383(14):1340-48.
https://www.nejm.org/doi/10.1056/NEJMoa1917338?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
http://www.ncbi.nlm.nih.gov/pubmed/32997908?tool=bestpractice.com
[17]Kjaer SK, Dehlendorff C, Belmonte F, et al. Real-world effectiveness of human papillomavirus vaccination against cervical cancer. J Natl Cancer Inst. 2021 Oct 1;113(10):1329-35.
https://academic.oup.com/jnci/article/113/10/1329/6227603
http://www.ncbi.nlm.nih.gov/pubmed/33876216?tool=bestpractice.com
[18]Guo F, Cofie LE, Berenson AB. Cervical cancer incidence in young U.S. females after human papillomavirus vaccine introduction. Am J Prev Med. 2018 Aug;55(2):197-204.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054889
http://www.ncbi.nlm.nih.gov/pubmed/29859731?tool=bestpractice.com
[19]Falcaro M, Castañon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021 Dec 4;398(10316):2084-92.
http://www.ncbi.nlm.nih.gov/pubmed/34741816?tool=bestpractice.com
The studies highlight the importance of early vaccination in reducing risk. Vaccinating boys in the same schedule may contribute to indirect protection for unvaccinated women and increase immunity in the population overall.[21]Rahangdale L, Mungo C, O'Connor S, et al. Human papillomavirus vaccination and cervical cancer risk. BMJ. 2022 Dec 15;379:e070115.
https://www.bmj.com/content/379/bmj-2022-070115.long
http://www.ncbi.nlm.nih.gov/pubmed/36521855?tool=bestpractice.com
The majority of HPV-associated cancers are caused by HPV types 16 or 18 (approximately 70%), both of which are targeted by HPV vaccines.[26]Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518-27.
http://www.nejm.org/doi/full/10.1056/NEJMoa021641#t=article
http://www.ncbi.nlm.nih.gov/pubmed/12571259?tool=bestpractice.com
[61]Braaten KP, Laufer MR. Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol. 2008 Winter;1(1):2-10.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2492590
http://www.ncbi.nlm.nih.gov/pubmed/18701931?tool=bestpractice.com
HPV vaccines are characterised by valency:[62]Restrepo J, Herrera T, Samakoses R, et al. Ten-year follow-up of 9-valent human papillomavirus vaccine: immunogenicity, effectiveness, and safety. Pediatrics. 2023 Oct 1;152(4):e2022060993.
https://publications.aap.org/pediatrics/article/152/4/e2022060993/193886/Ten-Year-Follow-up-of-9-Valent-Human
http://www.ncbi.nlm.nih.gov/pubmed/37667847?tool=bestpractice.com
Bivalent (protects against HPV types 16 and 18)
Quadrivalent (protects against HPV types 6, 11, 16, and 18)
9-valent (protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58).
HPV vaccines are licensed for use in two- or three-dose schedules; however, evidence from long-term studies suggests that a single dose offers protection comparable to two doses.[63]Kreimer AR, Sampson JN, Porras C, et al. Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial. J Natl Cancer Inst. 2020 Oct 1;112(10):1038-46.
https://publications.aap.org/pediatrics/article/152/4/e2022060993/193886/Ten-Year-Follow-up-of-9-Valent-Human
http://www.ncbi.nlm.nih.gov/pubmed/32091594?tool=bestpractice.com
[64]Basu P, Malvi SG, Joshi S, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 2021 Nov;22(11):1518-29.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00453-8/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/34634254?tool=bestpractice.com
[65]Barnabas RV, Brown ER, Onono MA, et al. Efficacy of single-dose HPV vaccination among young African women. NEJM Evid. 2022 Jun;1(5):EVIDoa2100056.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172784
http://www.ncbi.nlm.nih.gov/pubmed/35693874?tool=bestpractice.com
The World Health Organization recommends a one- or two-dose schedule for girls aged 9 to 20 years and a two-dose schedule for women over 21 years.[66]World Health Organization. Human papillomavirus vaccines: WHO position paper, December 2022 [internet publication].
https://www.who.int/publications/i/item/who-wer9750-645-672
UK vaccination schedule
In the UK, HPV vaccination is recommended for all adolescents (boys and girls) aged 12-13 years.[67]UK Health Security Agency. Human papillomavirus (HPV): the green book, chapter 18a. Jun 2023 [internet publication].
https://www.gov.uk/government/publications/human-papillomavirus-hpv-the-green-book-chapter-18a
A single dose of the 9-valent vaccine is recommended.[68]UK Health Security Agency. HPV vaccination guidance for healthcare practitioners (version 6). Jun 2023 [internet publication].
https://www.gov.uk/government/publications/hpv-universal-vaccination-guidance-for-health-professionals/hpv-vaccination-guidance-for-healthcare-practitioners
UKHSA: routine childhood immunisations
Opens in new window
Those eligible in the UK national programme can be vaccinated up to age 25 years, including those coming to the UK from overseas who have not been vaccinated.
A 3-dose schedule with doses at 0, 1, and 4-6 months should be offered to people with HIV and those known to be immunocompromised at the time of immunisation.[68]UK Health Security Agency. HPV vaccination guidance for healthcare practitioners (version 6). Jun 2023 [internet publication].
https://www.gov.uk/government/publications/hpv-universal-vaccination-guidance-for-health-professionals/hpv-vaccination-guidance-for-healthcare-practitioners
US vaccination schedule
In the US, HPV vaccination with the 9-valent vaccine is routinely recommended at age 11-12 years (but can start at age 9 years).[69]Saslow D, Andrews KS, Manassaram-Baptiste D, et al. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA Cancer J Clin. 2020 Jul;70(4):274-80.
https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21616
http://www.ncbi.nlm.nih.gov/pubmed/32639044?tool=bestpractice.com
[70]Centers for Disease Control and Prevention. Child and adolescent immunization schedule by age. Nov 2024 [internet publication].
https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html
The recommended schedule is:[70]Centers for Disease Control and Prevention. Child and adolescent immunization schedule by age. Nov 2024 [internet publication].
https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html
Two intramuscular injections at 0 and 6-12 months where vaccination is initiated before age 15 years, or
Three intramuscular injections at 0, 1-2, and 6 months where vaccination is initiated at age 15 years or older.
People with HIV or other immunocompromising conditions should receive three doses of HPV vaccine, even if vaccination is initiated between ages 9 and 14 years, because their response to vaccination may be attenuated.[71]National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. 2024 [internet publication].
https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf
Children with a history of sexual abuse or assault should be given the HPV vaccine as early as possible (starting at age 9 years).[72]American College of Obstetricians and Gynecologists' Committee on Adolescent Health Care, American College of Obstetricians and Gynecologists' Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group. Human papillomavirus vaccination: ACOG committee opinion, number 809. Obstet Gynecol. 2020 Aug;136(2):e15-21.
https://journals.lww.com/greenjournal/fulltext/2020/08000/human_papillomavirus_vaccination__acog_committee.48.aspx
http://www.ncbi.nlm.nih.gov/pubmed/32732766?tool=bestpractice.com
Catch-up vaccination is recommended for people through age 26 years (and may be considered with shared decision-making for those ages 27 years and over) who were not adequately vaccinated when younger.[70]Centers for Disease Control and Prevention. Child and adolescent immunization schedule by age. Nov 2024 [internet publication].
https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html
HPV vaccination is not recommended during pregnancy (although no intervention is needed if vaccination is given inadvertently during pregnancy).[69]Saslow D, Andrews KS, Manassaram-Baptiste D, et al. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA Cancer J Clin. 2020 Jul;70(4):274-80.
https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21616
http://www.ncbi.nlm.nih.gov/pubmed/32639044?tool=bestpractice.com
[72]American College of Obstetricians and Gynecologists' Committee on Adolescent Health Care, American College of Obstetricians and Gynecologists' Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group. Human papillomavirus vaccination: ACOG committee opinion, number 809. Obstet Gynecol. 2020 Aug;136(2):e15-21.
https://journals.lww.com/greenjournal/fulltext/2020/08000/human_papillomavirus_vaccination__acog_committee.48.aspx
http://www.ncbi.nlm.nih.gov/pubmed/32732766?tool=bestpractice.com
[73]Centers for Disease Control and Prevention. Adult immunization schedule by age. Nov 2024 [internet publication].
https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html
The American College of Obstetricians and Gynecologists (ACOG) recommends HPV vaccination in breastfeeding women ages 26 years and younger who have not previously been vaccinated.[72]American College of Obstetricians and Gynecologists' Committee on Adolescent Health Care, American College of Obstetricians and Gynecologists' Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group. Human papillomavirus vaccination: ACOG committee opinion, number 809. Obstet Gynecol. 2020 Aug;136(2):e15-21.
https://journals.lww.com/greenjournal/fulltext/2020/08000/human_papillomavirus_vaccination__acog_committee.48.aspx
http://www.ncbi.nlm.nih.gov/pubmed/32732766?tool=bestpractice.com
Further details of current US vaccination schedules, including catch-up vaccinations and special patient populations can be found in the latest ACIP vaccination schedules for children and adults.[70]Centers for Disease Control and Prevention. Child and adolescent immunization schedule by age. Nov 2024 [internet publication].
https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html
[73]Centers for Disease Control and Prevention. Adult immunization schedule by age. Nov 2024 [internet publication].
https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html
Barrier contraception and intrauterine devices
HPV is spread by skin-to-skin sexual contact; therefore, safe sexual health and effective barrier contraception may play a role in primary prevention.[74]Parazzini F, Negri E, La Vecchia C, et al. Barrier methods of contraception and the risk of cervical neoplasia. Contraception. 1989 Nov;40(5):519-30.
http://www.ncbi.nlm.nih.gov/pubmed/2692961?tool=bestpractice.com
However, the issue is complex.[75]Erbelding EJ, Zenilman JM. Toward better control of sexually transmitted diseases. N Engl J Med. 2005 Feb 17;352(7):720-1.
http://www.ncbi.nlm.nih.gov/pubmed/15716568?tool=bestpractice.com
[76]Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007 Nov 24;370(9601):1764-72.
http://www.ncbi.nlm.nih.gov/pubmed/17919718?tool=bestpractice.com
Use of an intrauterine device may reduce the risk of cervical cancer.[77]Cortessis VK, Barrett M, Brown Wade N, et al. Intrauterine device use and cervical cancer risk: a systematic review and meta-analysis. Obstet Gynecol. 2017 Dec;130(6):1226-36.
http://www.ncbi.nlm.nih.gov/pubmed/29112647?tool=bestpractice.com
[78]Spotnitz ME, Natarajan K, Ryan PB, et al. Relative risk of cervical neoplasms among copper and levonorgestrel-releasing intrauterine system users. Obstet Gynecol. 2020 Feb;135(2):319-27.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012337
http://www.ncbi.nlm.nih.gov/pubmed/31923062?tool=bestpractice.com
[79]Minalt N, Caldwell A, Yedlicka GM, et al. Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review. Am J Obstet Gynecol. 2023 Aug;229(2):93-100.
http://www.ncbi.nlm.nih.gov/pubmed/37001577?tool=bestpractice.com